In the long struggle against one of humanity's most lethal cancers, a new kind of medicine has quietly redrawn the boundary of what survival can mean. A large clinical trial conducted in China found that ivonescimab, a bispecific antibody targeting two tumor-sustaining pathways at once, extended the lives of advanced lung cancer patients by more than eight months compared to the current immunotherapy standard, pembrolizumab. The finding, emerging from nearly 400 patients followed over several years, represents not merely a statistical milestone but a reminder that the architecture of disease c
Ivonescimab Extends Survival in Advanced Lung Cancer vs. Pembrolizumab
The trial enrolled 398 patients with advanced lung cancer; ivonescimab demonstrated improved survival outcomes reducing mortality risk by 27% compared to standard treatment.
Eight months longer to live, with no new safety concerns.
Mark
So this drug kept people alive eight months longer on average. That's a real difference—but I want to understand what we're comparing. Is ivonescimab replacing chemotherapy, or is it replacing another immunotherapy?
Mimi
It's replacing pembrolizumab, which is already an immunotherapy. Both are checkpoint inhibitors, but ivonescimab is what they call a bispecific antibody—it hits two targets at once instead of one. So it's not chemotherapy versus immunotherapy; it's a newer immunotherapy versus the current standard.
Luke
Right, and that matters because pembrolizumab is already pretty good. The patients on it lived 22.6 months on average. That's not nothing. The question is whether an eight-month difference in a trial of 398 people in China will hold up in other populations and real-world use.
Mimi
Fair point. But the trial was randomized, the difference was statistically significant, and it held across subgroups. The safety profile was similar, so you're not trading survival for tolerability.
Mark
What about the patients with lower PD-L1 expression? The data there looked less clear.
Luke
Exactly. In patients with PD-L1 levels between 1 and 49 percent, the hazard ratio was 0.85 with a confidence interval that crossed 1.0—meaning we can't say with confidence that ivonescimab was better in that group. The benefit was clearest in high PD-L1 patients.
Mimi
Which makes sense biologically. If your tumor is expressing more of the target, the drug should work better. But it does mean this isn't a universal win for everyone with advanced lung cancer.
Mark
The drug is already approved in China. What happens next?
Mimi
That's the question. These results will go to regulators in other countries. Whether they approve it depends on how they weigh an eight-month survival benefit against the cost and the fact that it's a new drug with less long-term data than pembrolizumab.
Luke
And we should note: this trial was done in China, enrolled Chinese patients, and was presented at a conference. We don't have the full published data yet. The results are promising, but the full picture will come when this is published in a peer-reviewed journal.
The Pulse
- Advanced non-small cell lung cancer remains one of the deadliest diagnoses a patient can receive, and the urgency to improve on existing immunotherapy has never been greater.
- The HARMONi-2 trial placed 398 patients at the center of a direct contest between the established standard and a dual-targeting challenger — a design that left little room for ambiguity in its results.
- Ivonescimab's 27% reduction in mortality risk and 8.2-month median survival advantage over pembrolizumab sent a clear signal that blocking both PD-1 and VEGF simultaneously may be more powerful than blocking either alone.
- Subgroup analyses deepened the story: patients with squamous histology and those with the highest PD-L1 expression appeared to benefit most, offering clinicians early clues about who gains the most.
- Safety profiles remained broadly comparable, with serious adverse events only modestly higher in the ivonescimab arm, suggesting the added benefit does not come at a dramatically greater cost to patients.
- Already approved in China since April 2025, ivonescimab now carries overall survival data — the metric patients care about most — as it moves toward potential regulatory consideration in other parts of the world.
In the long struggle against one of humanity's most lethal cancers, a new kind of medicine has quietly redrawn the boundary of what survival can mean. A large clinical trial conducted in China found that ivonescimab, a bispecific antibody targeting two tumor-sustaining pathways at once, extended the lives of advanced lung cancer patients by more than eight months compared to the current immunotherapy standard, pembrolizumab. The finding, emerging from nearly 400 patients followed over several years, represents not merely a statistical milestone but a reminder that the architecture of disease can sometimes be outmaneuvered by the architecture of science.
A clinical trial presented at a major cancer conference this week has shown that ivonescimab, a newer immunotherapy drug, kept patients with advanced lung cancer alive significantly longer than pembrolizumab, the current standard of care. The trial, known as HARMONi-2, enrolled 398 patients in China between late 2022 and mid-2023, all of whom had PD-L1-positive tumors and had never previously received cancer treatment.
Patients were randomly assigned to receive either ivonescimab or pembrolizumab intravenously every three weeks. When survival data were analyzed through August 2026, those on ivonescimab had lived a median of 30.8 months, compared to 22.6 months for those on pembrolizumab — an eight-month difference that translated to a 27 percent reduction in the risk of death. The result was statistically significant.
What makes ivonescimab distinct is its dual mechanism: unlike pembrolizumab, which targets only the PD-1 pathway to help the immune system attack tumors, ivonescimab simultaneously blocks VEGF, a protein that helps tumors build the blood vessels they need to grow. This two-pronged approach appears to confer a meaningful advantage, though researchers continue to investigate exactly why.
The benefit was consistent across patient subgroups. Those with squamous cell lung cancer and those with the highest levels of PD-L1 expression showed the strongest responses. Even patients with lower PD-L1 levels trended toward benefit, though that finding did not reach statistical significance. Safety was broadly comparable between the two drugs, with only slightly higher rates of serious adverse events in the ivonescimab group and similarly low rates of treatment discontinuation.
Ivonescimab was already approved in China in April 2025 based on earlier data showing it slowed disease progression. These overall survival results — the measure most meaningful to patients — now strengthen its standing as a potential chemotherapy-free first-line option. Whether the findings will translate to broader global populations and regulatory approvals outside China remains the critical next question.
A new immunotherapy drug has extended survival in patients with advanced lung cancer, according to results presented at a major cancer conference this week. The drug, ivonescimab, kept patients alive roughly eight months longer on average than the current standard treatment, pembrolizumab, in a large clinical trial conducted in China.
The trial, called HARMONi-2, enrolled 398 patients with advanced non-small cell lung cancer between November 2022 and August 2023. All participants had tumors that expressed PD-L1, a protein marker that predicts response to immunotherapy, and none had received prior cancer treatment. Researchers randomly assigned half to receive ivonescimab and half to receive pembrolizumab, the established first-line immunotherapy for this patient population. Both drugs were given intravenously every three weeks.
When researchers analyzed survival data through August 2026, the difference between the two treatments became clear. Patients treated with ivonescimab lived a median of 30.8 months from the start of treatment, compared with 22.6 months for those receiving pembrolizumab. That eight-month gap translated to a 27 percent reduction in the risk of death. The finding was statistically significant, meaning it was unlikely to have occurred by chance. Ivonescimab had already received regulatory approval in China in April 2025 based on earlier data showing it slowed cancer progression faster than pembrolizumab, but this overall survival benefit—the measure that matters most to patients—represents a more substantial clinical achievement.
Ivonescimab works differently than pembrolizumab. It is a bispecific antibody, meaning it targets two separate pathways simultaneously: PD-1, which helps the immune system recognize and attack cancer cells, and VEGF, which promotes the growth of new blood vessels that feed tumors. Pembrolizumab targets only PD-1. This dual approach appears to offer an advantage, though the mechanism behind the survival benefit remains an area for further investigation.
The survival benefit held up across different patient subgroups. Among patients with squamous cell lung cancer, a particularly aggressive form, the hazard ratio was 0.65, indicating a stronger benefit. For those with non-squamous histology, it was 0.79. Patients with the highest levels of PD-L1 expression—at least 50 percent of tumor cells—saw a hazard ratio of 0.58, suggesting they benefited most from ivonescimab. Even patients with lower PD-L1 levels showed a trend toward benefit, though the result was not statistically significant in that subgroup.
Safety remained comparable between the two treatments. Nearly all patients in both groups experienced some treatment-related side effect. Serious adverse events occurred in about 30 percent of ivonescimab recipients and 22 percent of those receiving pembrolizumab. Immune-related adverse events, which reflect the drugs' mechanism of action, occurred at similar rates in both arms. Only 4.1 percent of patients on ivonescimab and 5.0 percent on pembrolizumab had to stop treatment permanently due to side effects.
The trial's results position ivonescimab as a chemotherapy-free option for patients newly diagnosed with advanced lung cancer that expresses PD-L1. In China, where the drug is already approved, it may become a standard first-line choice. For patients in other countries, the findings add to the evidence that will inform regulatory decisions and clinical practice guidelines. The next step will be to see whether these results, generated in a Chinese patient population, translate to other populations and whether additional trials in other regions will lead to broader approval.
Notable Quotes
Ivonescimab significantly prolonged overall survival versus pembrolizumab in this patient population, and retained a comparable safety profile with extended follow-up.— Prof. Caicun Zhou, Shanghai East Hospital
Want the full story?
Read the original at News-Medical ↗
Health & Medicine